赛隆药业集团股份有限公司关于公司股票可能被终止上市的第二次风险提示公告

Core Viewpoint - SAILONG Pharmaceutical Group Co., Ltd. is at risk of being delisted due to negative net profit and insufficient revenue, as indicated by their financial forecasts and previous announcements [2][3][9]. Group 1: Financial Performance and Risks - The company reported a negative net profit for the fiscal year 2024, with audited revenue below 300 million yuan, leading to a "delisting risk warning" effective April 28, 2025 [2][5]. - For the fiscal year 2025, the company anticipates revenue between 410 million yuan and 530 million yuan, with a projected net loss between 91 million yuan and 151 million yuan [3][9]. - The company’s equity attributable to shareholders is expected to be between 340 million yuan and 410 million yuan by the end of 2025 [3][9]. Group 2: Regulatory Compliance and Announcements - The company is required to issue risk warning announcements every ten trading days following the initial warning until the annual report is disclosed [4]. - This announcement marks the second risk warning regarding potential delisting, following an initial warning issued on January 31, 2026 [10]. - The company emphasizes the importance of timely and accurate information disclosure in compliance with legal regulations [11]. Group 3: Asset Transfer and Corporate Actions - The company is in the process of publicly transferring 100% equity of its wholly-owned subsidiary, Hunan Sailong Biopharmaceutical Co., Ltd., with an initial listing price set at 86.95 million yuan [15]. - As of February 12, 2026, no interested buyers were found during the initial listing period, prompting the company to consider further actions regarding the transfer [16].